Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Curevac rides the Covid wave

Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.

Vantage logo

Legend joins the billion-dollar club

With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.